Special Issue

Antibody Fc Biology in Disease and Therapy

Message from the Guest Editor

Antibodies are one of the most successful biomolecules as therapeutic agents, but we still do not know exactly what immune responses antibodies induce in adaptive and innate immunities. The antibody IgG, for example, binds to a several Fc receptors (six FcRs, complement C1q, FcRL5, FcRn, TRIM21, and type II lectin receptors). The interaction between antigen-bound antibodies (immune complexes, ICs) and Fc receptors is capable of eliciting a variety of known and unknown immune responses. Thus, in order to maximize the therapeutic efficacy of antibodies, a better understanding of Fc receptors is essential. In addition, the engineered antibodies that have modulated the binding ability to Fc receptors have begun to be used and show enhanced efficacies. Collectively, a better understanding of antibody functions in disease and therapy will provide the basis for developing new concepts of therapeutic antibodies. This Research Topic will focus on (i) the diverse immunological functions of the Fc receptors and (ii) new engineered antibodies based on Fc biology.

Guest Editor

Dr. Chang Han Lee

1. Department of Pharmacology, Seoul National University College of Medicine, Seoul, Republic of Korea
2. Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
3. Convergence Research Center for Dementia, Seoul National University Medical Research Center, Seoul, Republic of Korea
4. Wide River Institute of Immunology, Seoul National University, Hongcheon, Republic of Korea

Deadline for manuscript submissions

closed (31 December 2021)

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/si/67851

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

mdpi.com/journal/pharmaceutics

Pharmaceutics

an Open Access Journal by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed

mdpi.com/journal/pharmaceutics

About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, William Levine Hall, Room 225C, 160 Frelinghuysen Road, Piscataway, NJ 08854-8020, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).

MDPI